eQTL and multi-omics integration reveal PPIH as a prognostic and immunotherapeutic biomarker
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Peptidylprolyl isomerase H (PPIH) is identified as a potential pan-cancer biomarker. This gene promotes cancer cell proliferation and migration, offering new avenues for cancer diagnosis and targeted therapies.
Area Of Science
- Oncology
- Genomics
- Bioinformatics
Background
- Malignant tumors pose a significant global health challenge.
- Identifying novel biomarkers is crucial for advancing cancer diagnosis and treatment.
Purpose Of The Study
- To integrate multi-omics data for identifying a pan-cancer biomarker candidate.
- To evaluate the clinical applicability of the identified gene in oncology.
Main Methods
- Mendelian randomization using expression quantitative trait loci and genome-wide association study data.
- Multi-omics bioinformatics analyses including gene expression, genomic alterations, and tumor microenvironment (TME) associations.
- Single-cell transcriptome analysis and in vitro validation experiments.
Main Results
- Peptidylprolyl isomerase H (PPIH) identified as a potential pan-cancer biomarker.
- PPIH expression is abnormal and correlates with prognosis across multiple cancer types.
- In vitro studies show PPIH promotes hepatocellular carcinoma cell proliferation, migration, and invasion.
Conclusions
- PPIH emerges as a promising candidate biomarker with pan-cancer relevance.
- Findings support PPIH's potential clinical value in cancer diagnosis.
- This research lays the groundwork for developing targeted therapeutic strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.